Beam Therapeutics (BEAM) Capital Expenditures (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Capital Expenditures data on file, last reported at $2.2 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $2.2 million, up 53.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 6.06% YoY), and the FY2025 annual result was $1.3 million, up 52.4% from the prior year.
• Capital Expenditures grew to $2.2 million in Q1 2026 per BEAM's latest filing, from -$1.9 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $43.3 million in Q4 2022 and troughed at -$23.2 million in Q3 2022.
• A 5-year average of $5.1 million and a median of $3.6 million in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures sank 243.27% in 2024, then surged 2811.66% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $43.3 million in 2022, then sank by 91.71% to $3.6 million in 2023, then slumped by 243.27% to -$5.1 million in 2024, then surged by 63.92% to -$1.9 million in 2025, then jumped by 220.32% to $2.2 million in 2026.
• Business Quant data shows BEAM's Capital Expenditures at $2.2 million in Q1 2026, -$1.9 million in Q4 2025, and -$3.1 million in Q3 2025.